1-(2-PHENOXYMETHYLHETEROARYL) PIPERIDINE AND PIPERAZINE COMPOUNDS
申请人:Stangeland Eric L.
公开号:US20130324550A1
公开(公告)日:2013-12-05
The invention relates to compounds of formula I:
where X, HAr, a, and R
1
through R
6
are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
申请人:Stangeland Eric L.
公开号:US08530663B2
公开(公告)日:2013-09-10
The invention relates to compounds of formula I:
where X, HAr, a, and R1 through R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
[EN] 1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS<br/>[FR] COMPOSÉS DE 1-(2-PHÉNOXYMÉTHYLHÉTÉROARYL)PIPÉRIDINE ET PIPÉRAZINE
申请人:THERAVANCE INC
公开号:WO2011119461A1
公开(公告)日:2011-09-29
The invention relates to compounds of formula I: (I) where X, HAr, a, and R1 through R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS
申请人:Stangeland Eric L.
公开号:US20110230495A1
公开(公告)日:2011-09-22
The invention relates to compounds of formula I:
where X, HAr, a, and R
1
through R
6
are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.